NCI Trials for August 2021

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute approved the following clinical research studies last month.  

For further information, contact the principal investigator listed.

Phase I – 10363
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or Without HIV

NCI Center for Cancer Research
Lurain, Kathryn
(301) 250-5156

Phase I/II – 10417
Clinical Evaluation of ASTX727 in Combination with Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia

Yale University Cancer Center LAO
Savona, Michael Robert
(615) 936-3321

Phase I/II – 10428
A Phase I/II Study of Abemaciclib in Patients with HIV-Associated and HIV-Negative Kaposi Sarcoma

NCI Center for Cancer Research
Ramaswami, Ramya
(301) 451-9018

Phase II – NRG-BN010
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

NRG Oncology
Bagley, Stephen Joseph
(215) 614-1858

Phase III – URCC-19178
Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy

University of Rochester NCORP Research Base
Mohile, Supriya Gupta
(585) 275-9319

Phase Pilot – AMC-111
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study

AIDS Malignancy Consortium
Sigel, Keith Magnus
(212) 824-7558

Table of Contents


With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).